Minimal Residual Disease Detection of Myeloma Using Sequencing of IGH VDJ Regions
After therapy or stem cell transplantation, multiple myeloma patients achieving complete response or stringent complete response can still have a significant risk of disease relapse. This highlights the importance of using highly sensitive laboratory methods for minimal residual disease (MRD) detection and prognostication. Older methods such as allele-specific oligonucleotide real time quantitative polymerase chain reaction (ASO-RQ PCR) and fluorescent polymerase chain reaction (F-PCR) have their drawbacks.
Source: Seminars in Hematology - Category: Hematology Authors: Caleb Ho, Maria E. Arcila Source Type: research
More News: Hematology | Laboratory Medicine | Myeloma | Stem Cell Therapy | Stem Cells | Transplants